Please provide your email address to receive an email when new articles are posted on . Apremilast led to better clinical outcomes in early oligoarticular PsA vs. placebo at 16 weeks. Safety was ...
SAN FRANCISCO, CA—Longer-term efficacy and safety data from the Phase 3 PALACE 1 study have confirmed that apremilast at 20mg and 30mg twice-daily doses continues to demonstrate “sustained and ...
Researchers conducted a multicenter observational study across three major US academic medical centers with registries of patients with rheumatic immune-related adverse events to assess the ...
Please provide your email address to receive an email when new articles are posted on . Deucravacitinib showed significant improvement in plaque psoriasis compared with both placebo and apremilast, ...
WASHINGTON — In the phase 3 PALACE-1 trial, the investigational agent apremilast led to significant improvement in the signs and symptoms of psoriatic arthritis (PsA) in patients who failed to respond ...
SUMMIT, N.J.-- (BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today released new research findings on OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), ...
Review the side-effects of Apremilast as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
Improvements in disease severity and quality of life measures among adults with psoriasis who are receiving apremilast was independent of genital psoriasis involvement. Apremilast improves disease ...
Pediatric patients with plaque psoriasis receiving apremilast vs placebo experienced significantly greater improvements in global disease activity and skin involvement. Treatment with apremilast was ...
The small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behçet’s syndrome. In a phase 2 trial involving patients with Behçet’s syndrome, apremilast ...
The FDA has given approval for the use of apremilast in adults with active psoriatic arthritis—welcome news for patients and the rheumatology community. This commentary reviews some of the evidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results